The availability of the antifungal antibiotic amphotericin B necessitates its careful evaluation in the treatment of a heretofore uniformly fatal illness, torula meningitis. The recent past has seen other new and promising agents used, evaluated, and found to be wanting.1 Because central nervous system infections due to Cryptococcus neoformans may have long periods of spontaneous remission, final judgment of any specific therapy will have to await the test of time. However, if promising results are now obtained through the use of amphotericin B, physicians should be made aware so that no clinical case of torulosis goes untreated while the final data are being accumulated.
We are reporting this case of torula meningitis as an instance of the life-saving ability of amphotericin B. If the course of a steadily worsening illness is sharply and definitely reversed promptly after the beginning of a specific therapy, it behooves one to, at least,
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 6
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.